Evidence map›Paper›PMID 29650803›Full record

Trial reportDiabetes care2018

Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial.

Wen Wan, M Reza Skandari, Alexa Minc, Aviva G Nathan, Aaron Winn, Parmida Zarei, Michael O'Grady, Elbert S Huang

Open access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 6 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 6 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Pooled it
  2. Continuous glucose monitoring in type 2 diabetes: a systematic review of barriers and opportunities for care improvement.International journal for quality in health care : journal of the International Society for Quality in Health Care · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Wen WanSection of General Internal Medicine, University of Chicago, Chicago, IL wwan1@medicine.bsd.uchicago.edu.ORCID 0000-0002-7464-6563
M Reza SkandariSection of General Internal Medicine, University of Chicago, Chicago, IL.
Alexa MincSection of General Internal Medicine, University of Chicago, Chicago, IL.
Aviva G NathanSection of General Internal Medicine, University of Chicago, Chicago, IL.
Aaron WinnSchool of Pharmacy, Medical College of Wisconsin, Milwaukee, WI.
Parmida ZareiSection of General Internal Medicine, University of Chicago, Chicago, IL.
Michael O'GradyNational Opinion Research Center, University of Chicago, Chicago, IL.ORCID 0000-0002-0120-3155
Elbert S HuangSection of General Internal Medicine, University of Chicago, Chicago, IL.
University of Chicago · USMedical College of Wisconsin · US

Funding

Research Design, Data, and Analytics CoreP30DK092949 · NIDDK · UNIVERSITY OF CHICAGO · PI MILDA Renne SAUNDERS · 2011 to 2026
$10.0M
Research and Mentorship in Medical Decision Making in DiabetesK24DK105340 · NIDDK · UNIVERSITY OF CHICAGO · PI HUANG, ELBERT S. · 2015 to 2019
$884k
NIDDK NIH HHS K24 DK105340NIDDK NIH HHS P30 DK092949
6 · The paper itself

Abstract

objectiveThis study evaluated the societal cost-effectiveness of continuous glucose monitoring (CGM) in patients with type 1 diabetes (T1D) using multiple insulin injections. RESEARCH DESIGN AND

methodsIn the Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes (DIAMOND) trial, 158 patients with T1D and HbA

resultsWithin the 6-month trial, the CGM group had similar QALYs to the control group (0.462 ± 0.05 vs. 0.455 ± 0.06 years,

conclusionsFor adults with T1D using multiple insulin injections and still experiencing suboptimal glycemic control, CGM is cost-effective at the willingness-to-pay threshold of $100,000 per QALY, with improved glucose control and reductions in nonsevere hypoglycemia.

Indexed as

AdultAgedBlood GlucoseBlood Glucose Self-MonitoringCost-Benefit AnalysisDiabetes Mellitus, Type 1FemaleHumansHypoglycemiaHypoglycemic AgentsInsulinMaleMiddle AgedMonitoring, AmbulatoryBlood GlucoseHypoglycemic AgentsInsulin

Identifiers

PMID29650803
PMCPMC5961392
OpenAlexW2798025593

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.